TrialCell reports. Medicine2026

HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial results.

David A Braun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.